

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Betahistine Mesilate has obtained the approval for registration from the National Medical Products Administration of China (the “NMPA”) to become a bulk drug for the preparations on the market. Betahistine Mesilate is mainly used in the treatment of dizziness and lightheadedness associated with Meniere’s disease, Meniere’s syndrome and vertigo.

In addition, the Board is also pleased to announce that the Group’s Epinephrine has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Epinephrine is mainly used in the rescue of cardiac arrest and anaphylaxis, can be used in the treatment of other allergic diseases (such as bronchial asthma and urticaria), and can also be used in combination with local anesthetic to facilitate local hemostasis and help prolong drug effect.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 27 June 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.